Live biotherapeutics have been used clinically both as defined probiotics and as undefined faecal microbiota transplants. Two new studies illustrate the risks of administering live microorganisms to highly compromised patients. These risks should be considered in the context of the potential therapeutic value of these treatments.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019).
Hill, C. Virulence or niche factors: what’s in a name? J. Bacteriol. 194, 5725–5727 (2012).
U.S. Food & Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. fda.gov https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse (2019).
Lai, C. Y. et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment. Pharmacol. Ther. 49, 354–363 (2019).
Ott, S. J. et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gut 152, 799–811 (2017).
Dominguez-Bello, M. G. et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat. Med. 22, 250–253 (2016).
C.H. is a board member of the International Scientific Association of Probiotics and Prebiotics (ISAPP).
About this article
Cite this article
Hill, C. Balancing the risks and rewards of live biotherapeutics. Nat Rev Gastroenterol Hepatol 17, 133–134 (2020). https://doi.org/10.1038/s41575-019-0254-3